Showing posts with label Conditions and Diseases. Show all posts
Showing posts with label Conditions and Diseases. Show all posts

Wednesday, September 29, 2010

Science News I like!

Turmeric (Curcuma longa)Image via WikipediaScientists at the University of Leicester, funded by Hope Against Cancer, a Leciestershire based charity are pioneering the use of a common curry cooking ingredient to target cancer cells.

Dr Karen Brown, a Reader at the University, is the principal investigator of this new research, which is also being led by Dr Lynne Howells, of the and Biomarkers Group at the University.

The aim is use tissue from the colorectal tumours to effectively target chemo-resistant cells using curcumin, an extract of the commonly used root turmeric.

They will test their hypothesis using tissue from tumours extracted from patients undergoing surgery. Previous laboratory research has shown that curcumin, has not only improved the effectiveness of chemotherapy but has also reduced the number of chemo-resistant cells which has implications in preventing the disease returning.

ABOUT COLORECTAL CANCER

  • Accounts for over 600,000 deaths a year
  • The third leading cause of cancer deaths in the western world
  • The risk of developing increases with age
  • Studies show that a diet high in red meat and low in fresh fruit, vegetables, poultry and fish increases the risk of colorectal cancer
ABOUT TURMERIC:
  • Part of the ginger family
  • Native to south Asia
  • Orange/yellow powder is a spice for curries
  • Curcumin has an earthy, peppery flavour
  • It has been used for medicinal purposes for centuries
  • Its potential use in Alzheimer's, arthritis and other disorders is also being investigated around the world


Enhanced by Zemanta

Tuesday, September 21, 2010

Fundus photo showing focal laser surgery for d...Image via WikipediaMedWire reported that, according to a study published in the journal Diabetes, high serum levels of prolactin are associated with a decreased risk for diabetic retinopathy.
After working with rats and also measuring serum prolactin in 40 nondiabetic and 181 diabetic men with various degrees of retinopathy, researchers led by Carmen Clapp of the Cellular and Molecular Biology institute at the Institute of Neurobiology found that mean prolactin levels were higher in diabetic versus nondiabetic individuals (34.1 vs. 16.3 ng/ml), but lower in diabetic patients with proliferative retinopathy than in those without this complication (26.7 vs. 32.8 ng/ml). Notably, the results were the same, regardless of whether patients had type 1 or type 2 diabetes.
The researchers conclude that prolactin is an important systemic inhibitor of diabetes induced retinal hypervasopermeability after its intra ocular conversion into vasoinhibins.

Enhanced by Zemanta

Saturday, September 11, 2010

PHASE 3 STUDY OF CAN-FITE'S DRY EYE DRUG.

Can-Fite BioPharma Ltd. has opened an Investigational New Drug application (IND) with the FDA for a Phase 3 study of its lead drug, CF101, in patients with moderate to severe dry eye syndrome.
Dry eye syndrome is a chronic lack of sufficient lubrication and moisture on the surface of the eye. Its consequences range from subtle but constant irritation to ocular inflammation of the anterior (front) tissues of the eye. Dry eyes also are described by the medical term, keratitis sicca, which generally means decreased quality or quantity of tears
CF101 was found to be safe and well tolerated in an earlier Phase 2 study, in which the drug was taken orally as a monotherapy for 12 weeks.
According to Can-Fite, the randomized, double-masked, Phase 3 trial, which will enroll approximately 240 patients at multiple centers, will compare 2 doses of CF101 to placebo. The patients will be treated for 24 weeks and the main outcome assessments are improvement of corneal fluorescein staining, tear production and dry eye symptom score.
The National Women's Health Resource Center has named the top 100 dry eye hot spots in the United States based on information compiled from the National Oceanic and Atmospheric Administration's Climatic Data Center and the Environmental Protection Agency.
Factors used in the selection process included temperatures, humidity, wind, altitude, pollutants and ocular allergens.
The top 20 U.S. cities named as dry eye hot spots are:
1. Las Vegas, Nev.
2. Lubbock, Texas*
2. El Paso, Texas*
4. Midland/Odessa, Texas
5. Dallas/Fort Worth, Texas
6. Atlanta, Ga.
7. Salt Lake City, Utah
8. Phoenix, Ariz.
9. Amarillo, Texas
10. Honolulu, Hawaii
11. Oklahoma City, Okla.
12. Albuquerque, N.M.
13. Tucson, Ariz.
14. Norfolk, Va.
15. Newark, N.J.
16. Boston, Mass.
17. Denver, Colo.
18. Pittsburgh, Pa.
19. Bakersfield, Calif.*
19. Wichita, Kan.*
*Cities were tied for these spots.

Thursday, August 19, 2010

Radioactive discs in the eyes

Retinoblastoma retina scan before and after ch...Image via WikipediaJ. William Harbour, MD at Washington University School of Medicine in St. Louis is implanting radioactive discs in the eye as a treatment option for a rare type of cancer called retinoblastoma.

Retinoblastoma, as the name suggests, is characterized by tumors in the eye's retina. It is rare, affecting about one child in 20,000. In the United States, about 200 children each year are diagnosed with it. Approximately 40 percent of them develop tumors in both eyes, so in cases where the tumors prove resistant to chemotherapy, very young children and their parents are faced with a choice between a life without eyes and a high risk of death.

"The treatment plaque looks like a bottle cap made of gold," Harbour says. "Radiation seeds are placed on one side of the plaque, shining the radiation in one direction like a flashlight focused on the tumor. That prevents the radiation from affecting other parts of the body."

"The radiation causes damage within the cancer cells that prevents them from proliferating and spreading," he says. "By the time we take off the plaque, the cancer cells are either dead or mortally wounded, even though we do not immediately see a difference in the appearance of the tumor. After the plaque therapy, as the cancer cells try to proliferate and divide, those cells die, which we then notice in follow-up exams as the tumor shrinks over time."
Enhanced by Zemanta

Sunday, August 01, 2010

Tribal Clinic Working On Telemedecine

Low-resolution image of the Oregoh Health and ...Image via Wikipedia

Yellowhawk Tribal Health Center near Pendleton, OR, is one of two tribal clinics (the other is in Wichita, Kan.) working on a test of long-distance eye care with researchers from Oregon Health & Science University and Legacy Health's Devers Eye Institute. This effort waqs highlighted by The Oregonian

At Yellowhawk, patients with diabetes can undergo a retinal scan with a $20,000-plus non-mydriatic camera, which can photograph the retina without dilating the pupil. Next, the images are uploaded to the Internet and sent to doctors in Portland who check for signs of retinopathy. The images also allow doctors to check for glaucoma or macular degeneration.
Enhanced by Zemanta

Tuesday, July 20, 2010

Darker Skinned Individuals Also At Risk For Skin Cancer

Title: Pathology: Patient: Melanoma: Asymmetry...Image via Wikipedia

According to a study published in the Archives of Dermatology, darker skinned individuals are also at risk for skin cancer, particularly in geographic areas with intense sun exposure.

After analyzing data from the Florida Cancer Data System, looking at patterns of race- and sex-specific invasive melanoma trends between 1992 and 2004 and comparing them with national trends in the Surveillance, Epidemiology, and End Results (SEER) program, researchers found that melanoma rates increased in both registries among all groups, including blacks and Hispanics, particularly in Florida.

To date, however, most public-education programs about melanoma have primarily been directed to whites, so there may be less awareness of risk and the need for medical attention for suspicious lesions among darker skinned groups.
Enhanced by Zemanta

Friday, July 09, 2010

FDA Approves Implantable Telescope To Help Patients With AMD



FDA has approved a first-of-its-kind technology to counter a leading cause of blindness in older adults -- a tiny telescope implanted inside the eye.
The Implantable Miniature Telescope aims to help in the end stages of incurable age-related macular degeneration, although the FDA warned Tuesday that patients need post-surgery rehabilitation to make it work.

Dr. Malvina Eydelman, FDA's ophthalmic devices chief, said the device can improve the quality of life for those who are 75 and older, have a certain degree of vision loss and who also need a cataract removed. In addition, the FDA took the highly unusual step of requiring that patients and their surgeons sign a detailed 'acceptance of risk agreement' before surgery, acknowledging potential side effects -- including corneal damage and worsened vision -- and the need for lots of testing to determine who's a candidate.

The benefits of the telescopic implants are numerous, such as:

1. Improving the central vision acuity of patients.

2. Can be used in combination with drugs to treat macular degeneration and photodynamic thepray. The use of anti-hypertensive and anti-angiogenic drugs to treat wet advanced macular degeneration, a condition in which ocular arteries leak inside the eye, include ranibizumab and bevabizumab which can cost upto $2,000 per treatment. Ideally, these prosthetic implants will be offered to patients who have undergone photodynamic therapy to destroy "leaky" blood vessels of the eye before this implant can be made in one eye.

3. It may be more cost effective to use these telescopic implants for the treatment of both dry and wet age related macular degeneration over time compared to the continual, protracted and expensive use of drugs. With time, the dosage and use of these drugs can be reduced once the damaged tissue is healed and the implant has been placed in one of the affected eyes.

"The telescope implant represents a new category of treatment for this severely visually impaired population," said Allen W. Hill, CEO of VisionCare.



Enhanced by Zemanta

Friday, June 18, 2010

High HbA1c in Black compared with White people may falsify diabetes testing

Black individuals with diabetes and prediabetes have previously been shown to have higher levels of HbA1c than their White counterparts. However, there are little available data on links between ethnicity and HbA1c in nondiabetic individuals.

To investigate further, David Ziemer (Emory University, Atlanta, Georgia, USA) and colleagues recruited 1581 and 1967 non-Hispanic Black and White individuals without known diabetes from the SIGT (Screening for Impaired Glucose Tolerance) study and the NHANES III (Third National Health and Nutrition Examination) survey, respectively.

As reported in the Annals of Internal Medicine, the team found that HbA1c levels were 0.13% and 0.21% higher in Black than White participants with normal glucose tolerance (fasting plasma glucose [FPG] below 100 mg/dl) in the SIGT and NHANES III groups, respectively.
Enhanced by Zemanta

Monday, May 03, 2010

Latino Americans Have Higher Rates Of Blindness, Diabetic Eye Disease, Cataracts

According to four papers published in the May issue of the American Journal of Ophthalmology, "Latino Americans have higher rates of visual impairment, blindness, diabetic eye disease, and cataracts than whites in the United States."

In analyzing data from more than 4,600 participants in the Los Angeles Latino Eye Study (LALES), researchers found that the Latinos' rates of visual impairment and blindness were the highest of any ethnic group in the country, compared to other US studies of different populations.

"These data have significant public health implications and present a challenge for eye care providers to develop programs to address the burden of eye disease in Latinos," Dr. Paul A. Sieving, director of the National Eye Institute, said in the news release.

Reblog this post [with Zemanta]

Wednesday, October 28, 2009

MedPage Today reported that, according to a study presented at an ophthalmology meeting, "intravitreal injections of vascular endothelial growth factor (VEGF) inhibitors can cause persistent hypertension in the eye after only one treatment," a complication affecting 3.45 percent of patients given bevacizumab (Avastin) or ranibizumab (Lucentis) for age-related macular degeneration (AMD).
After "retrospectively" looking at 116 wet AMD patients treated with either VEGF inhibitor at their tertiary referral center from 2006 through 2008, researchers found that four patients developed persistent ocular hypertension. However, the ocular hypertension usually responds to antiglaucoma medication, though it returns if the drops are discontinued, the investigators said.


Reblog this post [with Zemanta]

Tuesday, October 20, 2009


The San Francisco Chronicle "City Brights" blog reported that anyone who spends two or more uninterrupted hours per day in front of a computer screen -- regardless of size -- is prone to Computer Vision Syndrome.
The condition is defined by the American Optometric Association as the complex of eye and vision problems related to near work, which are experienced during or related to computer use.

The most common symptoms associated with Computer Vision Syndrome (CVS) are

  • eyestrain
  • headaches
  • blurred vision
  • dry eyes
  • neck and shoulder pain

These symptoms may be caused by:

  • poor lighting
  • glare on the computer screen
  • improper viewing distances
  • poor seating posture
  • uncorrected vision problems
  • a combination of these factors

Currently, Dr. Harvey Moscot, a renowned Optometrist in New York City and a CVS specialist, is conducting a study to evaluate the effectiveness of specialized lenses for the reduction of CVS symptoms.

Reblog this post [with Zemanta]

Sunday, October 18, 2009

PHASE Ib CLINICAL TRIAL FOR AMD YIELDS PROMISING RESULTS.

OCT scan of a retina at 800nm with an axial re...Image via Wikipedia

MacuCLEAR, Inc. and Mystic Pharmaceuticals, Inc. have announced preliminary successful results of a Phase Ib Clinical Trial for the treatment and prevention of the progression of age-related macular degeneration (AMD). According to a press release from Mystic, the preliminary results indicated that MacuCLEAR's MC-1101 drug is safe and well tolerated by study participants, and has a biological effect on blood flow in the back of the retina. Trial participants used Mystic's VersiDoser ophthalmic delivery system to self-administer MC-1101 to the front of the eye during the trial. A key finding of the study was the successful migration of the drug to the back of the eye and the study included Proof of Concept (“POC”) indicators.


Reblog this post [with Zemanta]

Friday, October 09, 2009


Medscape reported that, according to a paper appearing online in Stroke, the risk for stroke, both ischemic and hemorrhagic, is increased by 30 percent within a year of "a herpes zoster attack," a figure that soars about four-fold should the attack involve the eye (herpes zoster ophthalmicus).

Researchers in Taipei reached those conclusions after scouring the Taiwan National Health Research Institute database to estimate the incidence of stroke among 7,760 adult patients treated for herpes zoster between 1997 and 2001, according to MedPage Today . Those patients were compared with 23,280 who had not been diagnosed with shingles.

The authors explained that the major mechanism of [their] findings is that stroke results from herpes zoster virus-induced vasculopathy [blood vessel damage].


The vessel to the brain damaged by the virus could be occluded [blocked] or ruptured lead investigator Dr. Jiunn-Horng Kang said.


Reblog this post [with Zemanta]

Friday, October 02, 2009

Vision impacts life success


MedPage Today reported that, according to a study published online in Ophthalmology, patients with age-related macular degeneration (AMD) have a 50 percent increased risk of coronary heart disease.



Researchers from the Singapore National Eye Center conducted a population-based cohort study of 1,786 patients who didn't have heart disease and 2,228 patients without stroke at baseline. Patients were between the ages of 69 and 97. The investigators found that those with early macular degeneration had a higher cumulative incidence of heart disease than those without (25.8 percent versus 18.9 percent).

Notably, there was a significantly higher cumulative incidence of heart disease for those with specific signs of early macular degeneration -- soft drusen, hyperpigmentation, and RPE depigmentation

Reblog this post [with Zemanta]

Monday, September 28, 2009

Researchers advancing new ways of helping blind people see


On its front page, the New York Times reported that 38 patients from the US, Europe, and Mexico are beginning an intensive three-year research project involving electrodes surgically implanted in their eyes, a camera on the bridge of their noses, and a video processor strapped to their waists, in a burst of recent research aimed at one of science's most-sought-after holy grails: making the blind see.



Researchers involved in the project, the artificial retina, say they have plans to develop the technology to allow people to read, write and recognize faces. Meanwhile, other approaches to treating blindness include gene therapy, which has produced improved vision in people who are blind from one rare congenital disease. Stem cell research is considered promising, although far from producing results, and other studies involve a light-responding protein and retinal transplants.

Reblog this post [with Zemanta]

Wednesday, September 02, 2009



According to a study in Wednesday's Journal of the American Medical Association, the antibiotic Zithromax [azithromycin], which is widely used in Africa to treat the eyesight-robbing infection trachoma, seems to help prevent Ethiopian children from dying of other diseases.

For the study, researchers from the Carter Center in Atlanta compared villages where children received the antibiotic Zithromax to villages where treatment was delayed a year. The antibiotic cut the death rate in half, and the researchers speculate it helped prevent deaths from pneumonia, diarrhea, and malaria, the biggest killers of Ethiopian children.

The AP notes that trachoma is caused by bacteria that spreads to the eyes from fingers, clothing or, some researchers think, from flies. Over the years, blindness develops through repeated infections and scarring.

Reblog this post [with Zemanta]

Friday, April 24, 2009

Possible cure for macular degeneration

The same view with age-related macular degener...Image via Wikipedia

There is new hope for people who suffer from macular degeneration.

Macular degeneration causes the center of your vision area to blur and deteriorate, but researchers say replacing cells in the filling wall of the retina could cure the condition.

"You're actually giving them a cell. This is a whole entity if you want to call it anything, and that's just a different way of looking at treating people. It truly is regeneration in terms of putting something back that is gone, so it's a major step forward," said Peter Coffey at the University College London.

Reblog this post [with Zemanta]

Twitter Delicious Facebook Digg Stumbleupon Favorites More

 
Design by Free WordPress Themes | Bloggerized by Lasantha - Premium Blogger Themes | Bluehost Review